-- FactSetが調査したアナリストによると、エクストラスペース・ストレージ（EXR）の平均投資判断は「オーバーウェイト」、平均目標株価は152ドルです。 （は、北米、アジア、ヨーロッパの主要銀行および調査会社による株式、商品、経済に関する調査レポートを配信しています。調査レポート提供者の方は、こちらからお問い合わせください：https://www..com/contact-us）
Price: $142.12, Change: $+1.59, Percent Change: +1.13%
Related Articles
Research
Research Alert: Amgn Q1 Tops Estimates Driven By Diversified Growth And Pipeline Investments
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Amgen delivered solid Q1 2026 results with revenues of $8.6B (+6% Y/Y), $50M above consensus, and non-GAAP EPS of $5.15 (+5% Y/Y), beating expectations by $0.38. The company demonstrated continued execution of its portfolio diversification strategy, with sixteen products achieving double-digit growth and seventeen products annualizing above $1B. We favorably view AMGN's broad-based growth across newer therapeutic franchises, with standout performances from Repatha (+34% Y/Y), TEPEZZA (+29% Y/Y), and TEZSPIRE (+20% Y/Y), offsetting expected declines in legacy products facing biosimilar competition. Management raised 2026 guidance to $37.1B-$38.5B in revenues and EPS of $21.70-$23.10. R&D expenses surged 16% Y/Y to $1.7B, reflecting intensive investments in the MariTide obesity program and multiple Phase 3 studies. We believe AMGN's successful portfolio transformation and strategic focus on high-growth therapeutic areas position it well for sustained long-term growth.
$AMGN
Research
Research Alert: Illumina: Sequencing Sales Growth Supports Q1 Eps Beat, Guidance Increased
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Illumina reported Q1 2026 adjusted EPS of $1.15, up 18.6% Y/Y and beating the $1.05 consensus estimate, while revenue grew 4.8% to $1.091B. Operating leverage was evident, with adjusted operating margin expanding 150 bps Y/Y to 21.9% due to consumables growth of 4.3% to $726M and instruments up 8.3% to $118M. The instrument growth suggests continued NovaSeq X adoption momentum, while rest-of-world organic revenue growth of 3.5% indicates healthy demand outside of China (declined 29% organically). ILMN raised full-year guidance, increasing revenue expectations by $20M at the midpoint to $4.52B-4.62B and adjusted EPS to $5.15-5.30 from $5.05-5.20. We view the recently-completed SomaLogic acquisition positively, as it expands ILMN's addressable market into proteomics and strengthens its multiomics portfolio. Strong cash generation was also present, with operating cash flow up 20.4% to $289M, supporting the newly-authorized $1.5B share repurchase program.
$ILMN
Research
Research Alert: CFRA Lowers Opinion On Shares Of Bxp, Inc. From Hold To Sell
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We decrease our target by $10 to $51, 7.5x our 2026 FFO estimate as occupancy headwinds remain with large capex increases now planned to improve leasing. We lower our 2026 FFO forecast by $0.05 to $6.82 and 2027's by $0.22 to $7.03. BXP's most concerning headline in Q1 was the increase in capex planned to drive 2026 leasing going from $220M-$250M all the way up to $400M. In our view, this indicates that vacant properties likely need significant concessions to tenants or redevelopment spending from BXP to improve structurally impaired occupancy. Management believes BXP stock is attractive now but unable to repurchase due to high leverage, which we consider concerning given the weakness in leasing and negative re-leasing spreads. Leasing improved in Q1 in San Francisco, but remains negative in Boston/New York (BXP's largest CBD markets). We expect further disposition activity ($400M more this year) and share issuance in 2026, with the goal of reducing leverage.
$BXP